Tag: Other OTC:RGBPP

Regen BioPharma Discusses Potential Impact of HemaXellerate on Chemotherapy Treament Market

SAN DIEGO, Aug. 15, 2025 (GLOBE NEWSWIRE) -- Regen BioPharma, Inc. (OTC ID: RGBP and RGBPP) today provided further insight into its planned Phase 1 clinical trial of HemaXellerate, the company’s innovative stem cell-derived therapy, which has already received U.S. FDA clearance. While the initial focus is on treating aplastic anemia, a rare orphan indication, Regen BioPharma is evaluating expanded applications for this groundbreaking therapy in markets poised for significant growth.

- A word from our sponsors -

Newsletter Signup

Name(Required)

First Last

Email(Required)

Enter Email Confirm Email

CAPTCHA

Privacy(Required)

I agree with the storage and handling of my data by this website. - Privacy Policy *

Name

This field is for validation purposes and should be left unchanged.

HomeTagsOther OTC:RGBPP

ROSEN, A LEADING INVESTOR RIGHTS LAW FIRM, Encourages Centene Corporation Investors to Secure Counsel Before Important Deadline in Securities Class Action – CNC

The United Steelworkers union condemns federal government interference in flight attendants’ bargaining rights

Le Syndicat des Métallos condamne l’ingérence du gouvernement fédéral dans la négociation des agent.e.s de bord d’Air Canada

Tag: Other OTC:RGBPP

Regen BioPharma Discusses Potential Impact of HemaXellerate on Chemotherapy Treament Market

Newsletter Signup

Explore

Press Releases

News & Opinion

Living

Others

Follow us